Filing Details
- Accession Number:
- 0001209191-18-041769
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-07-05 18:35:27
- Reporting Period:
- 2018-07-02
- Accepted Time:
- 2018-07-05 18:35:27
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1628738 | Audentes Therapeutics Inc. | BOLD | Biological Products, (No Disgnostic Substances) (2836) | 461606174 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1679129 | Suyash Prasad | C/O Audentes Therapeutics, Inc. 600 California Street, 17Th Floor San Francisco CA 94108 | Senior Vp & Chief Med Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-07-02 | 4,989 | $0.79 | 4,989 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-07-02 | 4,989 | $38.02 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2018-07-02 | 5,011 | $0.79 | 5,011 | No | 4 | M | Direct | |
| Copmmon Stock | Disposition | 2018-07-02 | 5,011 | $38.79 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2018-07-02 | 4,989 | $0.00 | 4,989 | $0.79 |
| Common Stock | Stock Option (right to buy) | Disposition | 2018-07-02 | 5,011 | $0.00 | 5,011 | $0.79 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 65,881 | 2024-02-18 | No | 4 | M | Direct | |
| 60,870 | 2024-02-18 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- Represents the weighted average sale price. The lowest price at which shares were sold was $37.465 and the highest price at which shares were sold was $38.37. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth in footnotes 2 and 3 to this Form 4.
- Represents the weighted average sale price. The lowest price at which shares were sold was $38.50 and the highest price at which shares were sold was $39.30.
- The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.
Billionaire Hedge Funds
